Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation

Cover Page

Cite item

Full Text

Abstract

Pure red cell aplasia (PRCA) is a rare complication of AB0-incompatible allogeneic hematopoietic stem cell transplantation, which manifests as a partial or complete absence of erythroid lineage in recipients with normal function of other hematopoietic lineages. There is a hypothesis, that lysis of erythroid precursors occurs because of antibody formation by population of residual B-lymphocytes and/or long-lived recipient’s plasma cells, which are capable for proliferation and active expression of the CD38 marker. That is why the invention of the IgG1 monoclonal antibody to CD38 presented as a new potentially effective targeted therapeutic option for patients with refractory PPCA. The article summarize clinical data on daratumumab for the therapy of PRCA in pediatric allogeneic hematopoietic stem cell transplantation recipients. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications.

About the authors

S. K. Arakelyan

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0009-0005-7866-7256

Moscow

Russian Federation

S. L. Blagov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: sblagov89@gmail.com
ORCID iD: 0000-0001-8754-1376

Sergey L. Blagov, hematologist

Hematopoietic Stem Cell Transplantation Department № 1

Moscow

Russian Federation

S. I. Kovrygin

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0009-0000-9389-4418

Moscow

Russian Federation

A. A. Semchenkova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-7082-1694

Moscow

Russian Federation

M. S. Fadeeva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-6553-2505

Moscow

Russian Federation

D. A. Evseev

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-8610-0624

Moscow

Russian Federation

T. Yu. Salimova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-2958-1705

Moscow

Russian Federation

D. D. Baidildina

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-7130-8596

Moscow

Russian Federation

L. N. Shelikhova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0003-0520-5630

Moscow

Russian Federation

M. A. Maschan

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0003-1735-0093

Moscow

Russian Federation

A. A. Maschan

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-0016-6698

Moscow

Russian Federation

References

  1. Балашов Д. Н. Особенности проведения трансфузионной терапии у пациентов после трансплантации гемопоэтических стволовых клеток. Обзор литературы / Д. Н. Балашов, П. Е. Трахтман // Онкогематология. – 2013. – (3): 42–7.
  2. Henig I., Yehudai-Ofir D., Zohar Y., Zuckerman T. Pure Red cell aplasia following ABO-mismatched allogeneic hematopoietic stem cell transplantation: resolution with daratumumab treatment. Acta Haematologica 2021; 144 (6): 683–87.
  3. Asawapanumas T., Chanswangphuwana C., Watanaboonyongcharoen P., Rojnuckarin P., Bunworasate U. Daratumumab as a frontline immunosuppression for pure red cell aplasia after major ABO-mismatched allogeneic hematopoietic stem cell transplantation. Leukemia Res Rep 2022; 17: 100314.
  4. Jeyaraman P., Borah P., Rajput P., Dayal N., Pathak S., Naithani R. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis 2021; 88: 102464.
  5. Rautenberg C., Kaivers J., Germing U., Haas R., Ackerstaff S., Hoffmann T., et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant 2020; 55 (6): 1191–3.
  6. Кучер М. А. Роль и оптимизация трансфузиологической тактики при трансплантации гемопоэтических стволовых клеток у онкологических и гематологических больных : Дис. … д-ра мед. наук. – СПб., 2018. – С. 27–8.
  7. Marco-Ayala J., Gómez-Seguí I., Sanz G., Solves P. Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transplant 2021; 56 (4): 769–78.
  8. Longval T., Galimard J. E., Leprêtre A. C., Suarez F., Amiranoff D., Cazaux M., et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol 2021; 193 (4): 814–26.
  9. Лушова А. А. Субпопуляции В-лимфоцитов: функции и молекулярные маркеры / А. А. Лушова [и др.] // Иммунология. – 2019. – 40 (6): 63–76.
  10. Сидорова Е. В. Долгоживущие В-клетки / Е. В. Сидорова // Успехи современной биологии. – 2013. – 133 (4): 333–48.
  11. Maschan A. A., Skorobogatova E. V., Balashov D. N., Pashanov E. D., Trakhtman P. E., Schipitzina I. P., et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 2002; 30 (6): 405–7.
  12. Gómez R. V., Vázquez G. V., Concepción V. N., García A. G., Saavedra C. A. Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther 2018; 11 (1): 44–6.
  13. Kopińska A., Helbig G., Frankiewicz A., Grygoruk-Wiśniowska I., Kyrcz-Krzemień S. Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation. Contemp Oncol (Pozn) 2012; 16 (3): 215–7.
  14. Chapuy C. I., Kaufman R. M., Alyea E. P., Connors J. M. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 2018; 379 (19): 1846–50.
  15. Bathini S., Holtzman N. G., Koka R., Singh Z., Wilding E., Zou Y., et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol 2019; 94 (8): 216–9.
  16. Salas M. Q., Alahmari A., Lipton J. H. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol 2020; 104 (2): 145–7.
  17. Martino R., García-Cadenas I., Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major AB0-mismatched allogeneic transplantation. Bone Marrow Transplant 2022; 57 (2): 282–5.
  18. Gangat N., Bleeker J., Lynch D., Olteanu H., Letendre L., Tefferi A. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica 2022; 107 (10): 2523–6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Arakelyan S.K., Blagov S.L., Kovrygin S.I., Semchenkova A.A., Fadeeva M.S., Evseev D.A., Salimova T.Y., Baidildina D.D., Shelikhova L.N., Maschan M.A., Maschan A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.